I-Mab (IMAB) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

I-Mab Third Quarter 2024 Earnings: US$0.25 Loss per Share (Vs US$0.57 Loss in 3Q 2023)
Yahoo FinanceNov 17 08:21 ET
I-Mab's Third Quarter Results: Progress in Cancer Immunotherapies
TipRanksNov 15 23:02 ET
H.C. Wainwright Maintains I-Mab(IMAB.US) With Buy Rating, Maintains Target Price $8
Moomoo NewsNov 15 07:33 ET · Ratings
I-MAB Receives Buy Rating as Uliledlimab and Givastomig Show Promising Clinical Progress
TipRanksNov 15 06:35 ET · Ratings
Express News | HC Wainwright & Co. Reiterates Buy on I-MAB, Maintains $8 Price Target
BenzingaNov 15 06:30 ET
I-MAB Analyst Ratings
BenzingaNov 15 06:29 ET · Ratings

Comments

Teddy123

Oct 30 06:16

I-Mab to Present Givastomig Phase 1 Optimal Dose Estimation Data at SITC 2024

$I-Mab (IMAB.US)$
ROCKVILLE, Md., Oct. 30, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced the presentation of a poster highlighting Phase 1 optimized dose estimation data for givastomig monotherapy (TJ033721/ABL111), a novel first-in-class Claudin18....

Update

$I-Mab (IMAB.US)$ Mab Reports Poster Presentation Highlighting Top-line Results From Its Ongoing Phase 1 Clinical Study Of Givastomig AT ESMO 2024
Benzinga· 1 min ago
Expanded Phase 1 monotherapy study of givastomig, a Claudin 18.2 X 4-1BB bispecific antibody immunostimulant, shows promising single-agent activity in heavily pre-treated patients with gastric cancers expressing Claudin 18.2 at low and high levels.The recommended Phase 2 dose for givastomig was determined to be 8-12 mg/kg; giv...

1

Jaguar8

Sep 10 06:55

NEWS

$I-Mab (IMAB.US)$
I-Mab Presents Positive Uliledlimab Pharmacokinetics Data at 2024 World Conference on Lung Cancer
- Pharmacokinetic/pharmacodynamic (PK/PD) modeling data from three Phase 1 studies providing dosing support for upcoming clinical trials
- Exposure-Response (E-R) Analysis showed a positive correlation between uliledlimab concentration and ORR probability in mNSCLC patients
- Randomized Phase 2 study of uliledlimab in combination with pembrolizumab plus chemotherapy expected to ...

Moomoo Breakfast US

Sep 12, 2022 07:36

Columns Today's Pre-Market Stock Movers: BMY, ADBE, MSTR, AZN and More

Gapping up
Select biotech/pharma names showing strength following ESMO:
$Clovis Oncology (CLVS.US)$ +11.3%, $Cardiff Oncology (CRDF.US)$ +9%, $Immatics (IMTX.US)$ +8.3%, $IDEAYA Biosciences (IDYA.US)$ +8%, $Lyra Therapeutics (LYRA.US)$ +5.7%, $POINT Biopharma (PNT.US)$ +5.7%, $Edgewise Therapeutics (EWTX.US)$ +4.7%, $Concert Pharmaceuticals (CNCE.US)$ +3.6%, $Deciphera Pharmaceuticals (DCPH.US)$ +3.2%, $Veracyte (VCYT.US)$ +2.6%, $SpringWorks Therapeutics (SWTX.US)$ +2.3%,...

10

IMAB I-Mab

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target